On the contrary, decreased levels of GH/IGF-I promote the development of NAFLD, and supplementation of recombinant GH in individuals with GH deficiency reversed hepatic steatosis (4, 5). This evidence concerns the gene GH1 and metabolic dysfunction-associated steatotic liver disease.